https://www.selleckchem.com/pr....oducts/pnd-1186-vs-4
Osimertinib is a novel and irreversible epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeting sensitive mutations and exon20 p.T790M mutation, which demonstrated superior progression-free survival (PFS) and overall survival (OS). We report a patient with lung adenocarcinoma harboring exon 19 deletion mutant treatment with icotinib. After 6 months, she developed exon20 p.T790M and then the patient received osimertinib treatment. A novel (exon41)- (exon12) fusion and exon20 p.T790M loss were identified
Like
Comment
Share
